GNRH1 and ovarian hyperstimulation syndrome: In comparison to the agonist protocol, the rapid onset and shorter half-lives of GnRH antagonists lead to decreased levels of E2, potentially mitigating the likelihood of ovarian hyperstimulation syndrome [15, 16].